4890.T
Tsubota Laboratory Incorporated
グロース · 医薬品 · 医薬品 · JP
JPY 300.00
+1.69%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 710.0M | 200.0M | 1.4B | 673.0M | 954.0M |
| Cost of Revenue | 12.8M | 68.5M | 180.2M | 652.2M | 235.6M |
| Gross Profit | 12.0M | 131.6M | 1.2B | 21.4M | 719.1M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 229.6M | 919.4M | 941.4M | 670.9M | 552.1M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 229.6M | 919.4M | 941.4M | 670.9M | 552.1M |
| Cost and Expenses | 1.1B | 987.0M | 1.1B | 1.3B | 787.0M |
| Operating Income (EBIT) | (395.0M) | (787.0M) | 235.0M | (649.0M) | 167.0M |
| Non-Operating | |||||
| Interest Income | — | 3.0M | 961.0K | 18.0K | 18.0K |
| Interest Expense | 193.0K | 698.0K | 1.1M | 1.0M | 778.0K |
| Net Interest Income | — | 2.3M | (124.0K) | (987.0K) | (760.0K) |
| Other Non-Op Income/Expense | 15.5M | 26.9M | 46.0M | 13.2M | (22.8M) |
| Non-Operating Income (excl Interest) | 316.0K | 24.5M | 46.2M | 14.5M | 4.3M |
| EBT (Pre-Tax Income) | (202.1M) | (760.9M) | 281.0M | (636.4M) | 144.2M |
| Income Tax Expense | 237.0K | 950.0K | 75.3M | 4.9M | 54.0M |
| Bottom Line | |||||
| Net Income | (399.0M) | (761.0M) | 205.0M | (641.0M) | 90.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (399.0M) | (761.0M) | 205.0M | (641.0M) | 90.0M |
| Per Share | |||||
| Basic EPS | (¥16) | (¥30) | ¥8 | (¥25) | ¥4 |
| Diluted EPS | (¥16) | (¥30) | ¥8 | — | ¥4 |
| Revenue Per Share | ¥28 | ¥8 | ¥53 | ¥26 | ¥39 |
| Shares | |||||
| Basic Shares Outstanding | 25.7M | 25.8M | 25.6M | 25.5M | 24.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (766.0M) | 263.8M | (613.3M) | 206.2M |
| D&A | — | 21.0M | 28.8M | 35.7M | 39.2M |
| EBIT | (395.0M) | (787.0M) | 235.0M | (649.0M) | 167.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026